secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nkarta, Inc. (NKTX)
CIK:        0001787400
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0000950170-24-056870
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nkarta Q1 net loss $29.5M; cash $450M; NKX019 lupus dosing on track
-------------------------------------------------------------------

- Cash, equivalents and investments of $450.0M at March 31, 2024, including $240.1M from March offering.
- Net loss of $29.5M ($0.58 per share) for Q1 2024; R&D expense $25.2M, G&A $7.5M.
- First patient dosing with NKX019 in lupus nephritis expected H1 2024; IND cleared 4Q2023.
- Preliminary NKX019 compressed dosing data in NHL expected mid-2024; 4/4 re-treated patients achieved CR.
- Cash runway expected to fund operations into late 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787400/000095017024056870/0000950170-24-056870-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787400/000095017024056870/nktx-20240509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-056870

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer